Photo-driven advanced oxidation process (AOP) with pharmaceutical wastewater has been poorly investigated so far. This paper presents the results of an experimental investigation on the photocatalytic degradation of emerging pharmaceutical contaminant chloroquine (CLQ) in water using zinc oxide (ZnO) nanoparticles as the catalyst and solar light (SL) as the source of energy. The catalyst was characterized by X-ray powder diffraction (XRD), scanning electron microscopy (SEM), scanning electron microscopy-energy dispersive X-ray analysis (SEM-EDAX), and transmission electron microscopy (TEM). The effect of various operating parameters such as catalyst loading, the concentration of target substrate, pH, and the effect of oxidants and anions (salts) on the efficiency of degradation was tested. The degradation follows pseudo-first-order kinetics. Surprisingly, contrary to the observation in most photocatalytic studies, the degradation is more efficient under solar radiation, with 77% under solar (SL) irradiation and 65% under UV light in 60 min. The degradation leads to slow and complete COD removal through several intermediates identified by the liquid chromatography-mass spectrometry (LC-MS) technique. The results suggest the possibility of using inexpensive natural, non-renewable solar energy for the purification of CLQ-contaminated water, thereby enabling the reuse of scarce water resources.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936940PMC
http://dx.doi.org/10.1007/s11270-023-06148-4DOI Listing

Publication Analysis

Top Keywords

emerging pharmaceutical
8
scanning electron
8
electron microscopy
8
solar
5
degradation
5
solar photocatalysis
4
photocatalysis decontamination
4
water
4
decontamination water
4
water emerging
4

Similar Publications

Background: Approximately 30% of coronavirus disease 2019 COVID-19 patients develop fatigue and psychological symptoms. We previously demonstrated the efficacy of donepezil, an acetylcholinesterase inhibitor that is widely used to treat dementia, in basic research.

Methods: This is a multicenter, double-blind, randomized, controlled, phase II clinical trial in which 120 patients with COVID-19 will be randomized in a 1:1 ratio to a donepezil or placebo group.

View Article and Find Full Text PDF

Aim: Vertebral artery dissection (VAD) is a rare cause of non-traumatic subarachnoid hemorrhage (SAH) with significant clinical implications. This study compared the clinical characteristics and outcomes of SAH from intracranial VAD rupture to those from other etiologies, primarily aneurysmal rupture.

Methods: This single-center retrospective cohort study at Okayama University Hospital included patients with non-traumatic SAH diagnosed between 2019 and 2023.

View Article and Find Full Text PDF

Female genital tuberculosis (FGTB) arises from infection and can rarely be caused by or atypical mycobacteria. FGTB usually arises from tuberculosis (TB) that affects the lungs or other organs. The infection can enter the vaginal tract directly from abdominal TB or by hematogenous or lymphatic pathways.

View Article and Find Full Text PDF

In this study, we investigated the measurable residual leukemic stem cell (MR-LSC) population after allogeneic stem cell transplantation (allo-SCT) for high-risk acute myeloid leukemia (AML), utilizing T-cell immunoglobulin mucin-3 (TIM-3) expression as a functional marker of AML leukemic stem cells (LSCs). Analysis of the CD34CD38 fraction of bone marrow cells immediately after achievement of engraftment revealed the presence of both TIM-3LSCs and TIM-3 donor hematopoietic stem cells (HSCs) at varying ratios. Genetic analysis confirmed that TIM-3 cells harbored patient-specific mutations identical to those found in AML clones, whereas TIM-3 cells did not, indicating that TIM-3CD34CD38 cells represent residual AML LSCs.

View Article and Find Full Text PDF

Background: Immunotherapy, including the use of immune checkpoint inhibitors such as nivolumab, is increasingly common in cancer treatment and can lead to various immune-related adverse effects, including rare cases of diabetic ketoacidosis. This case report highlights an unique instance of nivolumab-induced diabetic ketoacidosis in a patient without prior history of diabetes, emphasizing the importance of careful monitoring even in those without traditional risk factors.

Case Presentation: We report a case of a 70-year-old Caucasian male with metastatic esophageal adenocarcinoma who developed diabetic ketoacidosis 3 weeks after stopping nivolumab therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!